Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS)
CNY 108.11
(4.87%)
CNY 108.11
(4.87%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 356.2 Million CNY | 9.24% |
| 2022 | 276.14 Million CNY | 50.0% |
| 2021 | 184.09 Million CNY | 566.19% |
| 2020 | 27.63 Million CNY | 183.06% |
| 2019 | -33.26 Million CNY | -8073.11% |
| 2018 | 417.25 Thousand CNY | 108.2% |
| 2017 | -5.08 Million CNY | -12650.2% |
| 2016 | 40.53 Thousand CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 100.85 Million CNY | 21.11% |
| 2024 Q2 | 109.76 Million CNY | 8.83% |
| 2024 Q3 | 133.89 Million CNY | 21.98% |
| 2023 Q4 | 83.28 Million CNY | 45.56% |
| 2023 FY | 301.66 Million CNY | 9.24% |
| 2023 Q3 | 57.21 Million CNY | -44.35% |
| 2023 Q2 | 102.81 Million CNY | 2.18% |
| 2023 Q1 | 100.62 Million CNY | 5.92% |
| 2022 FY | 276.14 Million CNY | 50.0% |
| 2022 Q3 | 84.18 Million CNY | 48.69% |
| 2022 Q2 | 56.62 Million CNY | 40.36% |
| 2022 Q1 | 40.34 Million CNY | -54.81% |
| 2022 Q4 | 94.99 Million CNY | 12.84% |
| 2021 Q2 | 40.35 Million CNY | 449.88% |
| 2021 Q1 | -11.53 Million CNY | -3368.7% |
| 2021 FY | 184.09 Million CNY | 566.19% |
| 2021 Q4 | 89.27 Million CNY | 63.93% |
| 2021 Q3 | 54.45 Million CNY | 34.93% |
| 2020 Q4 | -332.55 Thousand CNY | -101.19% |
| 2020 Q3 | 27.96 Million CNY | 42408.61% |
| 2020 Q1 | - CNY | 100.0% |
| 2020 FY | 27.63 Million CNY | 183.06% |
| 2020 Q2 | -66.1 Thousand CNY | 0.0% |
| 2019 FY | -33.26 Million CNY | -8073.11% |
| 2019 Q4 | -175.8 Thousand CNY | 0.0% |
| 2019 Q3 | - CNY | 100.0% |
| 2019 Q2 | -245.41 Thousand CNY | 0.0% |
| 2019 Q1 | - CNY | 100.0% |
| 2018 Q4 | -83.46 Thousand CNY | 0.0% |
| 2018 FY | 417.25 Thousand CNY | 108.2% |
| 2017 FY | -5.08 Million CNY | -12650.2% |
| 2016 FY | 40.53 Thousand CNY | 0.0% |